10-Q: Third Harmonic Bio Announces Plan of Dissolution Despite Phase 1 Success of THB335

Third Harmonic Bio reveals plans to liquidate and dissolve the company, distributing remaining cash to stockholders, despite positive Phase 1 clinical trial results for THB335.

Summary

• Third Harmonic Bio, Inc. has announced a plan of dissolution, intending to liquidate the company and distribute remaining cash to stockholders.
• This decision follows a strategic review and approval by the Board of Directors.
• The company plans to complete Phase 2 readiness activities for THB335 by mid-year 2025 to maximize its value for a potential asset sale.
• If stockholders approve the dissolution, the company expects to file a Certificate of Dissolution in the third quarter of 2025.
• The company estimates a total distribution to stockholders between $5.13 and $5.42 per share, with an initial distribution expected in the third quarter of 2025.
• The company's net loss for the three months ended March 31, 2025, was $15.8 million, and it had cash and cash equivalents of $271.6 million as of that date.
• The company believes its existing cash will be sufficient to fund operations through at least 2026.
• In February 2025, the company implemented a restructuring plan, halting non-THB335 research and reducing the workforce by approximately 50%.
• Research and development expenses increased to $10.6 million for the three months ended March 31, 2025, primarily due to the THB335 program.
• General and administrative expenses increased to $8.1 million, driven by personnel-related expenses and stock-based compensation.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to the company's decision to dissolve despite positive clinical trial results. The company is returning cash to shareholders instead of continuing operations.

Positives

• The company has a substantial amount of cash and cash equivalents ($271.6 million as of March 31, 2025) which is expected to fund operations through at least 2026.
• The company is aiming to maximize stockholder value through a potential asset sale of the THB335 program.
• The company has completed Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.
• The company has a plan to distribute remaining cash to stockholders, with an estimated distribution of $5.13 to $5.42 per share.

Negatives

• The company is planning to liquidate and dissolve, indicating a lack of confidence in long-term growth.
• The company incurred a net loss of $15.8 million for the three months ended March 31, 2025.
• The company implemented a restructuring plan, halting non-THB335 research and reducing the workforce by approximately 50%, indicating a change in strategic direction.
• The company has no products approved for sale and has not generated any revenue from product sales.

Risks

• The amount distributed to stockholders may be less than estimated if liabilities or claims are higher than anticipated.
• The payment of the distribution to stockholders could be delayed.
• Stockholders may not be able to recognize a loss for U.S. federal income tax purposes until they receive a final distribution.
• The company's estimates regarding the Plan of Dissolution, including the expenses to satisfy outstanding obligations, liabilities and claims during the liquidation process, may be inaccurate.
• The company may need to defend or resolve unforeseen claims or establish a reasonable reserve before making distributions to stockholders.
• The company may retain for distribution at a later date some or all of the estimated amounts that it expects to distribute to stockholders.
• The company may be unable to obtain funding on a timely basis or on acceptable terms, which may force the company to delay, limit or terminate its product development programs, commercialization efforts or other operations.

Future Outlook

The company plans to complete Phase 2 readiness activities for THB335 by mid-year 2025 to maximize its value for a potential asset sale and expects to file a Certificate of Dissolution in the third quarter of 2025, pending stockholder approval.

Management Comments

• The Board of Directors determined that the liquidation and dissolution of the Company and the distribution of remaining cash to stockholders is advisable and in the best interests of the Company and its stockholders.

Industry Context

The biopharmaceutical industry is characterized by high risk and uncertainty, with many companies facing setbacks in clinical trials and difficulties in obtaining regulatory approval. Third Harmonic Bio's decision to dissolve, despite positive clinical trial results, highlights the challenges faced by smaller companies in a competitive landscape.

Comparison to Industry Standards

• Many biopharmaceutical companies, especially those in early stages, rely on venture capital or partnerships with larger firms to fund operations.
• Third Harmonic Bio's decision to liquidate contrasts with the typical industry trajectory of seeking further funding or acquisition after positive clinical data.
• Comparable companies in the mast cell-mediated disease space include Celldex Therapeutics, Jasper Therapeutics, and Blueprint Medicines, all of which are pursuing clinical development and commercialization strategies.
• The decision to dissolve and distribute cash to shareholders is an unusual outcome, as most companies in this sector would seek to continue operations or be acquired.

Related Party Transactions

• Novartis is a significant beneficial owner of the Company, holding more than 5% of the total outstanding stock of the Company.
• The Company has an in-license agreement with Novartis, which required the Company to make an upfront payment and issue shares of Series A-1 Preferred Stock to Novartis, and further includes future milestone payments upon the occurrence of certain events and royalty payments upon future sales.
• On August 9, 2021, the Company entered into the Promissory Note with the CEO for an amount of $ 1.8 million, which was used to allow the CEO to purchase 1,218,836 shares of common stock granted in the form of a restricted stock award under the 2019 Plan.

Stakeholder Impact

• Stockholders will receive a distribution of remaining cash, estimated between $5.13 and $5.42 per share.
• Employees have been impacted by the restructuring plan, with a reduction in workforce of approximately 50%.
• Patients may be impacted by the discontinuation of research and development activities for non-THB335 programs.
• Suppliers and vendors may be impacted by the company's plan to dissolve.

Next Steps

• Complete Phase 2 readiness activities for THB335 by mid-year 2025.
• Seek stockholder approval for the Dissolution and Plan of Dissolution on June 5, 2025.
• File a Certificate of Dissolution with the Secretary of the State of Delaware in the third quarter of 2025, if stockholders authorize the Dissolution.

Key Dates

Keywords

dissolution, liquidation, THB335, stockholders, cash distribution, clinical trial, KIT inhibitor, financial results, restructuring, biopharmaceutical